Want to see GB:CIZ full AI Analyst Report?
CIZ Stock Chart & Stats
1.55 p
<0.01 p(0.26%)
At close: 4:00 PM EST
1.55 p
<0.01 p(0.26%)
Day’s Range― - ―
52-Week Range1.20 p - 3.90 p
Previous CloseN/A
Volume291.66K
Average Volume (3M)1.23M
Market Cap
£9.14M
Enterprise Value12.21M
Total Cash (Recent Filing)£116.00K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta-0.58
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding424,963,200
10 Day Avg. Volume655,017
30 Day Avg. Volume1,232,506
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-18.07
Price to Sales (P/S)0.00
P/FCF Ratio-12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported near-zero debt materially reduces default and interest burden risk for a pre-revenue biotech. Low leverage preserves financial flexibility to fund R&D through equity, partnerships, or grants, making the firm less vulnerable to credit shocks over the next 2–6 months.
Focused Oncology Diagnostics MarketA clear focus on blood-based early lung-cancer diagnostics targets a large, enduring unmet need in oncology screening and early detection. If clinical validation progresses, this niche offers structural commercial upside via high clinical demand and potential partnerships with healthcare providers and diagnostic companies.
Cash-flow TransparencyFree cash flow tracking net income indicates limited large non-cash accounting distortions, making cash-burn estimates more reliable. For planning R&D milestones and fundraising, transparent cash conversion helps management and investors assess realistic runway and capital needs over several months.
Bears Say
Pre-revenue With Persistent LossesBeing pre-revenue with ongoing operating losses means the business lacks internally generated funding to advance development or commercialize. This creates sustained reliance on external capital, increases dilution risk, and limits the company's ability to scale or absorb development setbacks in the coming months.
Balance-sheet DeteriorationShrinking assets and equity turning negative signal an eroding capital base. A negative equity position constrains financing options, can complicate partner or vendor relationships, and heightens the urgency for capital raises, which may occur on unfavorable terms and hinder long-term program funding.
Consistent Negative Operating Cash FlowSustained negative operating cash flow reflects continuous cash burn to fund R&D and operations. Persistent outflows shorten runway, force recurrent fundraising, and increase execution risk for clinical validation timelines, which can delay commercialization and erode shareholder value over time.
Cizzle Biotechnology Holdings PLC News
CIZ FAQ
What was Cizzle Biotechnology Holdings PLC’s price range in the past 12 months?
Cizzle Biotechnology Holdings PLC lowest share price was 1.20 p and its highest was 3.90 p in the past 12 months.
What is Cizzle Biotechnology Holdings PLC’s market cap?
Cizzle Biotechnology Holdings PLC’s market cap is £9.14M.
When is Cizzle Biotechnology Holdings PLC’s upcoming earnings report date?
Cizzle Biotechnology Holdings PLC’s upcoming earnings report date is Sep 24, 2026 which is in 71 days.
How were Cizzle Biotechnology Holdings PLC’s earnings last quarter?
Cizzle Biotechnology Holdings PLC released its earnings results on Apr 30, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Cizzle Biotechnology Holdings PLC overvalued?
According to Wall Street analysts Cizzle Biotechnology Holdings PLC’s price is currently Overvalued.
Does Cizzle Biotechnology Holdings PLC pay dividends?
Cizzle Biotechnology Holdings PLC does not currently pay dividends.
What is Cizzle Biotechnology Holdings PLC’s EPS estimate?
Cizzle Biotechnology Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cizzle Biotechnology Holdings PLC have?
Cizzle Biotechnology Holdings PLC has 424,963,200 shares outstanding.
What happened to Cizzle Biotechnology Holdings PLC’s price movement after its last earnings report?
Cizzle Biotechnology Holdings PLC reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.636%.
Which hedge fund is a major shareholder of Cizzle Biotechnology Holdings PLC?
Currently, no hedge funds are holding shares in GB:CIZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.